Working… Menu

Non-inferiority Clinic of Kollagenase® Compared Iruxol® in Treatment of Cutaneous Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00701974
Recruitment Status : Suspended
First Posted : June 19, 2008
Last Update Posted : October 25, 2010
Information provided by:
Azidus Brasil

Brief Summary:

Skin ulcers can be defined as open injuries, loss of substances with the skin or mucous tissue, caused by disintegration and tissue necrosis. Chronic skin ulcer is any injury that heal in a period not less than 6 weeks. Several etiological causes for the emergence of skin ulcers. Around 73% are venous, arterial are 8%, 3% are diabetic, 2% are traumatic and 14% are from other causes.

Clinical studies show that collagenase is an effective drug and presents high tolerabildade in the treatment of ulcerative burns and injuries of various etiologies. Evidence show statistically significant reduction of inflammation, the formation of granulation tissue, decrease in injuries and reepitelization.

Condition or disease Intervention/treatment Phase
Ulcers Biological: collagenase (IRUXOL) Biological: collagenase (Kollagenase) Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Study of Non Inferiority of Product Kollagenase ®, Manufactured by Laboratory Cristália When Compared With Iruxol ®, Manufactured by Abbott Laboratory, in the Treatment of Cutaneous Ulcers
Study Start Date : February 2008
Actual Primary Completion Date : February 2008

Arm Intervention/treatment
Experimental: 1
patients treated with collagenase (IRUXOL)
Biological: collagenase (IRUXOL)
patients will be treated with collagenase one time per day.

Experimental: 2
patients treated with collagenase (Kollagenase)
Biological: collagenase (Kollagenase)
patients will be treated with collagenase one time per day.

Primary Outcome Measures :
  1. Primary: Non-inferiority based on efficiency that will be evaluated by the general improvement of the injury; Secondary: tolerability assessed by the incidence of adverse events. [ Time Frame: healing ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients of both sexes aged over 18 years
  • people with skin ulcers of the lower limbs for at least 3 months

Exclusion Criteria:

  • Lesion with a diameter larger than 12 cm ²
  • injury over 2 years of evolution; injury infected
  • neoplastic lesions in activity
  • poorly controlled diabetes mellitus
  • HAS poorly controlled
  • signs of ischemia in the limb
  • not offset any disease
  • allergic to components of formula
  • urticaria
  • pregnancy
  • breastfeeding
  • emotional disturbance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00701974

Layout table for location information
Lal Clinica
Valinhos, Sao Paulo, Brazil
Sponsors and Collaborators
Azidus Brasil

Layout table for additonal information
Responsible Party: Alexandre Frederico, LAL Clinica Identifier: NCT00701974     History of Changes
Other Study ID Numbers: COLCRI0208
First Posted: June 19, 2008    Key Record Dates
Last Update Posted: October 25, 2010
Last Verified: February 2008
Keywords provided by Azidus Brasil:
Non-inferiority based on efficiency
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Ulcer
Pathologic Processes
Skin Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action